...Aurora-A ) inhibitor for small cell lung cancer (SCLC). The other Phase IIb programs include TAK-228...

...generic mTOR antagonist rapamycin, which targets the protein's FRB domain, conjugated via a linker to TAK-228...
...FRB domain, kinase domain or both domains, the compound decreased viability compared with rapamycin plus TAK-228...
...compound decreased tumor growth with comparable potency to TAK-228. In a mouse xenograft model of TAK-228-resistant...

...treat solid tumors. Takeda Pharmaceutical Co. Ltd. also has three clinical stage compounds. MLN0128 ( INK128...

...studies. Exelixis Inc.'s XL388 is in preclinical development for cancer indications. Takeda Pharmaceutical Co. Ltd.'s INK128...

...inhibitor of phosphoinositide 3-kinase (PI3K) alpha ; IPI-145, a dual inhibitor of PI3K delta/gamma; and INK128...

...Intellikine in January for $190 million up front and up to $120 million in milestones. INK128...
...began partnering discussions two years ago. "We were impressed by how quickly Intellikine was moving INK128...
...perhaps other diseases, according to Curran. Takeda has specific combinations in mind. "Examples include combining INK128...

...far away. The other half is more of a stretch," said Sofinnova's Mike Powell. Intellikine's INK128...

...$190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128...

...$190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128...

...companies plan to use as they move forward with their PI3Kg program. Intellikine's lead compound, INK128...
...is in Phase I testing to treat advanced solid tumors and multiple myeloma (MM). INK128...